Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,492 JPY | +1.05% | +3.15% | -11.54% |
Sales 2024 * | 1,572B 10.16B | Sales 2025 * | 1,670B 10.79B | Capitalization | 2,674B 17.29B |
---|---|---|---|---|---|
Net income 2024 * | 17.45B 113M | Net income 2025 * | 135B 870M | EV / Sales 2024 * | 2.02 x |
Net Debt 2024 * | 503B 3.25B | Net Debt 2025 * | 448B 2.9B | EV / Sales 2025 * | 1.87 x |
P/E ratio 2024 * |
124
x | P/E ratio 2025 * |
19.6
x | Employees | 14,484 |
Yield 2024 * |
4.74% | Yield 2025 * |
5.03% | Free-Float | 98.83% |
Latest transcript on Astellas Pharma Inc.
1 day | +1.05% | ||
1 week | +2.76% | ||
Current month | -9.25% | ||
1 month | -9.80% | ||
3 months | -13.51% | ||
6 months | -22.86% | ||
Current year | -11.54% |
Managers | Title | Age | Since |
---|---|---|---|
Naoki Okamura
CEO | Chief Executive Officer | 61 | 86-03-31 |
Kitamura Atsushi
DFI | Director of Finance/CFO | 52 | Oct. 31 |
Kenji Yasukawa
CHM | Chairman | 63 | 86-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Takashi Tanaka
BRD | Director/Board Member | 67 | 21-05-31 |
Mamoru Sekiyama
BRD | Director/Board Member | 74 | 17-05-31 |
Naoki Okamura
CEO | Chief Executive Officer | 61 | 86-03-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
11.47% | 15 M€ | +6.12% | ||
2.09% | 251 M€ | +12.23% | ||
2.01% | 57 M€ | +16.88% | ||
1.99% | 11 M€ | +9.33% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-23 | 1,492 | +1.05% | 6 786 600 |
24-04-22 | 1,476 | -0.30% | 8,068,600 |
24-04-19 | 1,480 | +1.02% | 7,909,200 |
24-04-18 | 1,466 | -0.07% | 6,445,400 |
24-04-17 | 1,466 | +1.03% | 9,854,500 |
Delayed Quote Japan Exchange, April 23, 2024 at 02:00 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.54% | 17.1B | |
+26.37% | 659B | |
+26.47% | 557B | |
-5.05% | 359B | |
+17.01% | 322B | |
+9.12% | 297B | |
+6.25% | 215B | |
+5.18% | 210B | |
-5.97% | 200B | |
-8.41% | 149B |
- Stock Market
- Equities
- 4503 Stock